

February 5, 2019

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Unaudited Financial Results for the quarter ended December 31, 2018

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter ended December 31, 2018 which were approved by the Board of Directors of the Company, at its meeting held on February 5, 2019 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 3:30 p.m. and concluded at 6.30 p.m.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head – Legal & Company Secretary



Encl: As above

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report on the unaudited quarterly and year-to-date financial results of RPG Life Sciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
RPG Life Sciences Limited

We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 31 December 2018 and the period from 1 April 2018 to 31 December 2018 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 5 February 2019. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022



Himanshu Chapey
Partner

Membership No: 105731

Mumbai
5 February 2019

(Rs. in Lakhs)						
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018						
Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	9,097	9,050	9,566	26,136	26,368	34,714
2 Other Income	2	6	51	38	66	98
3 Total Income	9,099	9,056	9,617	26,174	26,434	34,812
4 Expenses						
(a) Cost of Materials Consumed	1,459	1,194	2,253	4,164	5,043	7,195
(b) Purchases of Stock-in-Trade	1,132	957	1,515	3,304	3,571	4,935
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	336	1,126	(434)	1,212	183	(669)
(d) Excise Duty Paid on sale of goods	-	-	-	-	319	319
(e) Employee Benefits Expense	2,394	2,386	2,313	7,002	6,527	9,014
(f) Finance Costs	99	105	93	308	297	380
(g) Depreciation and Amortisation Expense	386	381	360	1,138	1,066	1,434
(h) Other Expenses	2,568	2,597	2,717	7,753	7,831	10,168
Total Expenses	8,374	8,746	8,817	24,881	24,837	32,776
5 Profit before tax	725	310	800	1,293	1,597	2,036
6 Income tax expenses						
a. Current Tax	120	85	136	266	297	385
b. Deferred Tax	77	9	118	100	80	306
7 Profit for the period	528	216	546	927	1,220	1,345
8 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(6)	(6)	(23)	(18)	(69)	(22)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	2	-	6	-	8
Other Comprehensive Income Net of Tax	(4)	(4)	(23)	(12)	(69)	(14)
9 Total Comprehensive Income for the period	524	212	523	915	1,151	1,331
10 Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
11 Other Equity						14,152
12 Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	3.19	1.31	3.30	5.61	7.38	8.13
(b) Diluted	3.19	1.31	3.30	5.61	7.38	8.13

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 05, 2019. The Statutory Auditors of the Company have conducted a 'Limited Review' of the results for the quarter and nine months ended December 31, 2018.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- The Government of India introduced the Goods and Services Tax (GST) with effect from July 01, 2017, consequently revenue from operations for the quarters ended September 30, 2018, September 30, 2017 and June 30, 2018; for six months ended September 30, 2018 is net of GST. However revenue for all other periods presented is inclusive of excise duty, where applicable. The Net Revenue from operations (Net of GST/ Excise Duty) as applicable are stated below:

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
Revenue from Operations	9,097	9,050	9,566	26,136	26,368	34,714
Less: Excise Duty	-	-	-	-	319	319
Net Revenue from operations	9,097	9,050	9,566	26,136	26,049	34,395

- Effective April 1, 2018, the Company has adopted Ind AS 115 'Revenue from contracts with customers'. Based on the assessment done by the management, there is no material impact on the revenue recognised during the period.



For RPG Life Sciences Limited



Yugal Sikri
 Managing Director
 Mumbai, February 05, 2019